Merck Stock News

Merck (MRK) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.09 per share. This compares to earnings of $1.62 per share a year ago.

CNBC's Mike Santoli reports on the company's quarterly earnings results.

Merck posted a 3-cent a share loss on revenue of $14.6 billion in the fourth quarter. Analysts surveyed by FactSet had expected Merck to report an 11-cent loss on revenue of $14.5 billion.

Merck & Co on Thursday reported better-than-expected fourth-quarter results on strong sales of its cancer immunotherapy Keytruda, now the world's biggest selling prescription medicine.

Merck & Co. Inc. on Thursday reported fourth-quarter earnings and sales that beat analysts' expectations, powered by strong growth in cancer and vaccine products.

Merck still posted a quarterly loss due to previously announced charges associated with its cancer drug collaboration deal with Daiichi Sankyo.

You don't hear as much about the Dow Jones Industrial Average as investors did a few decades ago, as the broad consensus has deemed the S&P 500 a better indicator of market conditions.

J&J, Merck and Bristol Myers Squibb face a pivotal few weeks ahead. Meanwhile, Apple will reportedly explore health applications for the Vision Pro headset.

We expect GSK's specialty products like Arexvy, Cabenuva, Dovato, Bexsero, Trelegy Ellipta and Shingrix to drive fourth-quarter sales performance.

Pharmaceutical companies are due to receive by Thursday the U.S. government's opening proposal for discounts it is seeking on 10 high-cost medicines, an important step in the Medicare health program's

Merck is well on its way to replacing its most important growth driver. Fiverr will continue to benefit from the expanding gig economy.

Fast-approaching patent expirations will take a bite out of revenues and put the industry's top players in the hot seat over the next few years.

The CEOs of Merck, Johnson & Johnson and Bristol Myers Squibb will testify at the hearing on drug prices, Sen. Bernie Sanders said.

Healthcare had a mediocre performance in 2023, but it remains a suitable addition to a diversified portfolio due to its defensive characteristics. AbbVie Inc. and Merck & Co., Inc. are attractive heal

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.